Genentech’s next generation PI3-kinase inhibitor, GDC-0032, was the topic of two presentations yesterday at the 2013 annual meeting of the

 AACR 2013 GDC 0032 a next generation PI3K Inhibitor shows early promise in breast cancer

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $369 for 3 months access (does not auto renew), $598 for 6 months access (does not auto renew) and $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals contained within it.